Cell-type specific regulation of calreticulin and Bcl-2 expression by mood stabilizer drugs

European Neuropsychopharmacology

Volumn 14, Issue 2, 2004, Pages 143-150

  Corson, Timothy W ^a,b   Woo, Karen K ^a   Li, Peter P ^a,b,c   Warsh, Jerry J ^a,b,c  

^a CENTRE FOR ADDICTION AND MENTAL HEALTH   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

Author keywords

Bcl 2; Bipolar affective disorder; Calreticulin; Gene expression; Lithium; Valproic acid

Indexed keywords

CALRETICULIN; LITHIUM; OCTANOIC ACID; PROTEIN BCL 2; VALPROIC ACID;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; CELL SPECIFICITY; CELL TYPE; CONTROLLED STUDY; DRUG EFFECT; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GLIA CELL; HUMAN; HUMAN CELL; MOLECULAR BIOLOGY; NERVE CELL; NONHUMAN; PRIORITY JOURNAL; RAT;

EID: 0842328581     PISSN: 0924977X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0924-977X(03)00102-0     Document Type: Article

References (48)

1. Andreeff M., Jiang S., Zhang X., Konopleva M., Estrov Z., Snell V.E., Xie Z., Okcu M.F., Sanchez-Williams G., Dong J., Estey E.H., Champlin R.C., Kornblau S.M., Reed J.C., Zhao S. Expression of Bcl-2-related genes in normal and AML progenitors: changes induced by chemotherapy and retinoic acid. Leukemia. 13:1999;1881-1892.
2. Asghari V., Wang J.F., Reiach J.S., Young L.T. Differential effects of mood stabilizers on Fos/Jun proteins and AP-1 DNA binding activity in human neuroblastoma SH-SY5Y cells. Mol. Brain Res. 58:1998;95-102.
3. Balkham S.E., Sargent J.M., Elgie A.W., Williamson C.J., Taylor C.G. Comparison of BCL-2 and BAX protein expression with in vitro sensitivity to ARA-C and 6TG in AML. Adv. Exp. Med. Biol. 457:1999;335-340.
4. Behrens J., von Kries J.P., Kuhl M., Bruhn L., Wedlich D., Grosschedl R., Birchmeier W. Functional interaction of β-catenin with the transcription factor LEF-1. Nature. 382:1996;638-642.
5. Benda P., Lightbody J., Sato G., Levine L., Sweet W. Differentiated rat glial cell strain in tissue culture. Science. 161:1968;370-371.
6. Benes F.M., Vincent S.L., Todtenkopf M. The density of pyramidal and nonpyramidal neurons in anterior cingulate cortex of schizophrenic and bipolar subjects. Biol. Psychiatry. 50:2001;395-406.
7. Bhatia P., Taylor W.R., Greenberg A.H., Wright J.A. Comparison of glyceraldehyde-3-phosphate dehydrogenase and 28S-ribosomal RNA gene expression as RNA loading controls for northern blot analysis of cell lines of varying malignant potential. Anal. Biochem. 216:1994;223-226.
8. Bouras C., Kovari E., Hof P.R., Riederer B.M., Giannakopoulos P. Anterior cingulate cortex pathology in schizophrenia and bipolar disorder. Acta Neuropathol. 102:2001;373-379.
9. Bowden C.L., Brugger A.M., Swann A.C., Calabrese J.R., Janicak P.G., Petty F., Dilsaver S.C., Davis J.M., Rush A.J., Small J.G. Efficacy of divalproex vs lithium and placebo in the treatment of mania. The Depakote Mania Study Group. JAMA. 271:1994;918-924.
10. Bown C.D., Wang J.F., Young L.T. Increased expression of endoplasmic reticulum stress proteins following chronic valproate treatment of rat C6 glioma cells. Neuropharmacology. 39:2000;2162-2169.
11. Chen R.W., Chuang D.M. Long term lithium treatment suppresses p53 and Bax expression but increases Bcl-2 expression. A prominent role in neuroprotection against excitotoxicity. J. Biol. Chem. 274:1999;6039-6042.
12. Chen G., Yuan P., Hawver D.B., Potter W.Z., Manji H.K. Increase in AP-1 transcription factor DNA binding activity by valproic acid. Neuropsychopharmacology. 16:1997;238-245.
13. Chen B., Wang J.F., Hill B.C., Young L.T. Lithium and valproate differentially regulate brain regional expression of phosphorylated CREB and c-Fos. Brain Res. 70:1999;45-53.
14. Chen G., Zeng W.Z., Yuan P.X., Huang L.D., Jiang Y.M., Zhao Z.H., Manji H.K. The mood-stabilizing agents lithium and valproate robustly increase the levels of the neuroprotective protein bcl-2 in the CNS. J. Neurochem. 72:1999;879-882.
15. Chen G., Masana M.I., Manji H.K. Lithium regulates PKC-mediated intracellular cross-talk and gene expression in the CNS in vivo. Bipolar Disord. 2:2000;217-236.
16. Chen G., Rajkowska G., Du F., Seraji-Bozorgzad N., Manji H.K. Enhancement of hippocampal neurogenesis by lithium. J. Neurochem. 75:2000;1729-1734.
17. Chen B., Wang J.F., Young L.T. Chronic valproate treatment increases expression of endoplasmic reticulum stress proteins in the rat cerebral cortex and hippocampus. Biol. Psychiatry. 48:2000;658-664.
18. Chen G., Yuan P., Li J., Manji H.K. Low Bcl2 levels in frontal cortex in mood disorders and upregulation of Bcl2 by mood-stabilizers. Soc. Neurosci. Abstr. 27:2001;. (Program No. 353.9).
19. Chen G., Huang L.D., Zeng W.Z., Manji H.K. Mood stabilizers regulate cytoprotective and mRNA-binding proteins in the brain: long-term effects on cell survival and transcript stability. Int. J. Neuropsychopharmacol. 4:2001;47-64.
20. Daadi M.M., Saporta S., Willing A.E., Zigova T., McGrogan M.P., Sanberg P.R. In vitro induction and in vivo expression of bcl-2 in the hNT neurons. Brain Res. Bull. 56:2001;147-152.
21. de Leeuw W.J., Slagboom P.E., Vijg J. Quantitative comparison of mRNA levels in mammalian tissues: 28S ribosomal RNA level as an accurate internal control. Nucleic Acids Res. 17:1989;10137-10138.
22. Drevets W.C., Ongur D., Price J.L. Neuroimaging abnormalities in the subgenual prefrontal cortex: implications for the pathophysiology of familial mood disorders. Mol. Psychiatry. 3:1998;220-226.
23. Fadel M.P., Szewczenko-Pawlikowski M., Leclerc P., Dziak E., Symonds J.M., Blaschuk O., Michalak M., Opas M. Calreticulin affects β-catenin-associated pathways. J. Biol. Chem. 276:2001;27083-27089.
24. Feng L., Precht P., Balakir R., Horton W.E. Jr. Evidence of a direct role for Bcl-2 in the regulation of articular chondrocyte apoptosis under the conditions of serum withdrawal and retinoic acid treatment. J. Cell Biochem. 71:1998;302-309.
25. Freshney R.I. Culture of Animal Cells: A Manual of Basic Technique. 4th ed. 2000;Wiley-Liss, New York, NY.
26. Gething M.J., Sambrook J. Protein folding in the cell. Nature. 355:1992;33-45.
27. Gianni M., Ponzanelli I., Mologni L., Reichert U., Rambaldi A., Terao M., Garattini E. Retinoid-dependent growth inhibition, differentiation and apoptosis in acute promyelocytic leukemia cells. Expression and activation of caspases. Cell Death Differ. 7:2000;447-460.
28. Goidin D., Mamessier A., Staquet M.J., Schmitt D., Berthier-Vergnes O. Ribosomal 18S RNA prevails over glyceraldehyde-3-phosphate dehydrogenase and β-actin genes as internal standard for quantitative comparison of mRNA levels in invasive and noninvasive human melanoma cell subpopulations. Anal. Biochem. 295:2001;17-21.
29. Grimes C.A., Jope R.S. The multifaceted roles of glycogen synthase kinase 3β in cellular signaling. Prog. Neurobiol. 65:2001;391-426.
30. Kohlhoff S., Ziechmann C., Gottlob K., Graessmann M. SV40 T/t-antigens sensitize mammary gland epithelial cells to oxidative stress and apoptosis. Free Radic. Biol. Med. 29:2000;497-506.
31. Manji H.K., Potter W.Z., Lenox R.H. Signal transduction pathways. Molecular targets for lithium's actions. Arch. Gen. Psychiatry. 52:1995;531-543.
32. Manji H.K., Bebchuk J.M., Moore G.J., Glitz D., Hasanat K.A., Chen G. Modulation of CNS signal transduction pathways and gene expression by mood-stabilizing agents: therapeutic implications. J. Clin. Psychiatry. 60(Suppl. 2):1999;27-39.
33. Manji H.K., Moore G.J., Chen G. Lithium at 50: have the neuroprotective effects of this unique cation been overlooked? Biol. Psychiatry. 46:1999;929-940.
34. Manji H.K., Moore G.J., Chen G. Lithium up-regulates the cytoprotective protein Bcl-2 in the CNS in vivo: a role for neurotrophic and neuroprotective effects in manic depressive illness. J. Clin. Psychiatry. 61(Suppl. 9):2000;82-96.
35. Manji H.K., Moore G.J., Rajkowska G., Chen G. Neuroplasticity and cellular resilience in mood disorders. Mol. Psychiatry. 5:2000;578-593.
36. Moore G.J., Bebchuk J.M., Hasanat K., Chen G., Seraji-Bozorgzad N., Wilds I.B., Faulk M.W., Koch S., Glitz D.A., Jolkovsky L., Manji H.K. Lithium increases N-acetyl-aspartate in the human brain: in vivo evidence in support of bcl-2's neurotrophic effects? Biol. Psychiatry. 48:2000;1-8.
37. Nakamura K., Bossy-Wetzel E., Burns K., Fadel M.P., Lozyk M., Goping I.S., Opas M., Bleackley R.C., Green D.R., Michalak M. Changes in endoplasmic reticulum luminal environment affect cell sensitivity to apoptosis. J. Cell Biol. 150:2000;731-740.
38. Ozaki N., Chuang D.M. Lithium increases transcription factor binding to AP-1 and cyclic AMP-responsive element in cultured neurons and rat brain. J. Neurochem. 69:1997;2336-2344.
39. Rajkowska G. Postmortem studies in mood disorders indicate altered numbers of neurons and glial cells. Biol. Psychiatry. 48:2000;766-777.
40. Rajkowska G., Halaris A., Selemon L.D. Reductions in neuronal and glial density characterize the dorsolateral prefrontal cortex in bipolar disorder. Biol. Psychiatry. 49:2001;741-752.
41. Rao P.V. Statistical Research Methods in the Life Sciences. 1998;Duxbury Press, Pacific Grove, CA.
42. Schou M. The early European lithium studies. Aust. N. Z. J. Psychiatry. 33:1999;S39-S47. (Suppl.).
43. Suzuki T., Higgins P.J., Crawford D.R. Control selection for RNA quantitation. Biotechniques. 29:2000;332-337.
44. Unlap M.T., Jope R.S. Lithium attenuates nerve growth factor-induced activation of AP-1 DNA binding activity in PC12 cells. Neuropsychopharmacology. 17:1997;12-17.
45. Wang J.F., Asghari V., Rockel C., Young L.T. Cyclic AMP responsive element binding protein phosphorylation and DNA binding is decreased by chronic lithium but not valproate treatment of SH-SY5Y neuroblastoma cells. Neuroscience. 91:1999;771-776.
46. Wang J.F., Bown C., Young L.T. Differential display PCR reveals novel targets for the mood-stabilizing drug valproate including the molecular chaperone GRP78. Mol. Pharmacol. 55:1999;521-527.
47. Yuan P.X., Chen G., Huang L.D., Manji H.K. Lithium stimulates gene expression through the AP-1 transcription factor pathway. Mol. Brain Res. 58:1998;225-230.
48. Zhou R., Williams P.S., Yuan P., Manji H.K., Chen G. Valproate, an anticonvulsive and mood-stabilizing agent suppresses death genes and induces survival genes. Soc. Neurosci. Abstr. 27:2001;. (Program No. 218.15).